Immuneering Corporation is a clinical-stage oncology company that is devoted to developing drugs for cancer patients through universal RAS therapy. The company’s lead candidate product, IMM-1-104, is undergoing phase I/IIa clinical trials in patients with advanced solid tumors bearing RAS gene mutations. IMM-1-104 has been developed as an oral once-daily monotherapy aimed at achieving universal activity on RAS through deep cyclic inhibition of the MAPK pathway. The company’s second candidate product, IMM-6-415, aims to achieve universal MAPK activity through an accelerated oral administration twice daily, as well as deep cyclic inhibition of the MAPK pathway. IMM-6-415 is under investigation for a new drug application (IND) and potential studies. The pipeline also includes Trifecta MEK, a RAS modulator, and other small molecule drug discovery programs. The platform is based on two key elements: bioinformatics and 3D tumor modeling.
More information about the company.